Nureca Limited Reports Strong Q3 FY26 Performance with 50% Revenue Growth

Nureca Limited has announced strong financial results for Q3 FY26, demonstrating significant growth across key performance metrics. The digital-first healthcare company, which generates over 90% of its revenue through online sales, has shown remarkable improvement in both revenue and profitability indicators.

Financial Performance Highlights

The company's Q3 FY26 performance showcased substantial growth momentum with revenue from operations reaching ₹396.00 million, representing a robust 46% year-on-year increase from ₹272.00 million in Q3 FY25. The company achieved a remarkable turnaround in profitability with net profit of ₹32.00 million compared to a loss of ₹33.00 million in the previous year.

Metric	Q3 FY26	Q3 FY25	YoY Growth
Revenue from Operations	₹396.00 million	₹272.00 million	+46%
Net Profit	₹32.00 million	₹-33.00 million	Positive turnaround
GMV	₹540.00 million	₹425.00 million	+27%
EBITDA	₹54.00 million (13%)	₹25.40 million (-9%)	+314%

Nine-Month Performance

For the nine-month period ending December 31, 2025, Nureca maintained strong performance indicators across all key metrics.

Parameter	9M FY26 Performance
Revenue from Operations	₹1,126.00 million
GMV	₹1,536.00 million
EBITDA	₹130.00 million (11% margin)
PAT	₹82.00 million (7% margin)

Business Operations and Product Portfolio

Nureca operates as a debt-free, asset-light company with a healthy liquidity position. The company maintains an extensive product portfolio of 285+ active SKUs across multiple healthcare categories including massagers, blood pressure monitors, weighing scales, thermometers, orthopedic products, and respiratory care devices. During Q3 FY26, the company launched 8 new products, continuing its focus on innovation and market expansion.

The company's manufacturing subsidiary, Nureca Technologies Pvt Limited, has received 13 approvals from CDSCO and holds certifications including ISO 9001:2015 and ISO 13485:2016 from Intertek, along with USFDA 510K exempt approval for 7 products. The facility maintains an annual production capacity of 8 lakh units in India.

Digital Platform and Customer Base

Nureca's digital-first approach has resulted in a cumulative customer base of 1.75 crore users by 9M FY26, growing from 1.65 crore in FY25. The company's Dr Trust 360 connected health app has attracted 2.17 million users, offering both free and premium subscription-based health management services.

Regulatory Compliance

The company has updated its registered address details to "Andheri West B-205, Bldg -42, B wing, Dhanashree heights, Azad Nagar Sangam CHS, Andheri West, Mumbai – 400053" in its investor presentation, ensuring compliance with regulatory requirements under Regulation 30.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.25%	+13.86%	+17.30%	+23.77%	-17.30%	-50.14%

Nureca Limited has announced the successful completion of extinguishment of 4,58,255 equity shares following its buyback program conducted through stock exchange mechanism. The company informed stock exchanges on January 10, 2026, about the completion of this corporate action undertaken in compliance with SEBI (Buy-Back of Securities) Regulations, 2018 and the Companies Act, 2013.

Buyback Program Details

The buyback program was initiated following a public announcement dated December 01, 2025, which was published on December 02, 2025, and a letter of offer dated December 16, 2025. The tendering period commenced on Thursday, December 18, 2025, and concluded on Wednesday, December 24, 2025.

Parameter	Details
Buyback Price	₹330 per share
Face Value	₹10 per share
Tendering Period	December 18-24, 2025
Total Shares Bought Back	4,58,255
Extinguishment Date	January 07, 2026

Impact on Share Capital Structure

The extinguishment of shares has resulted in a significant reduction in the company's equity share capital. The reconciliation shows the pre and post-buyback capital structure changes.

Particulars	No. of Equity Shares	Equity Share Capital (₹)
Pre-Buyback Capital	1,00,00,175	10,00,01,750
Shares Extinguished	4,58,255	45,82,550
Post-Extinguishment Capital	95,41,920	9,54,19,200

Extinguishment Process and Compliance

The extinguishment process was executed in full compliance with Regulation 24(iv) read with Regulation 11 of the SEBI Buyback Regulations. All 4,58,255 shares were held in dematerialized form and were extinguished through National Securities Depository Limited (NSDL) on January 07, 2026.

The extinguishment was facilitated by Alankit Imaginations Limited (DP ID: IN300118) with company's client ID number 11846354. No physical shares were involved in this buyback program. The process received certification from multiple authorized signatories including the Managing Director, CEO-cum-Whole Time Director, Secretarial Auditor, and the Registrar and Share Transfer Agent.

Regulatory Confirmations

NSDL issued a confirmation letter dated January 07, 2026, confirming the debit of 4,58,255 shares from the company's demat account. The corporate action was executed by Alankit Assignments Limited, serving as the Registrar and Transfer Agent for the buyback program.

The company has fulfilled all regulatory requirements and obtained necessary certifications from authorized personnel, ensuring complete compliance with applicable buyback regulations. This buyback represents approximately 4.58% of the company's pre-buyback equity share capital.